AEON Biopharma (AEON) Registration Filing summary

Company overview and business model

• Focuses on developing prabotulinumtoxinA injection (ABP-450) for debilitating medical conditions as a biosimilar in the U.S. and other major markets.

• Holds exclusive development and distribution rights for certain therapeutic uses of ABP-450 in the U.S., Canada, EU, UK, and select international territories.

• ABP-450 is already approved as a biosimilar in Mexico and India and is marketed for aesthetic uses in the U.S., Canada, and EU under other brand names.

• Targets the global therapeutic botulinum toxin market, estimated at $3.0 billion and projected to reach $4.4 billion by 2027.

• Built a management team with deep experience in biopharmaceutical and botulinum toxin development and commercialization.

Financial performance and metrics

• As of June 30, 2024, net tangible book deficit was $(27.9) million, or $(0.71) per share.

• After a $50 million offering at $0.99 per share, as adjusted net tangible book value would be $20.0 million, or $0.22 per share.

• Immediate dilution to new investors in the offering is estimated at $0.77 per share.

• Recurring losses from operations, net capital deficiency, and negative cash flows raise substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds from offerings will be used for general corporate purposes and to fund continued development, approval, and commercialization of product candidates.

• Pending use, proceeds may be invested in short-term, investment-grade interest-bearing securities.